MoonLake Immunotherapeutics (MLTX)
45.26
+2.69
(+6.32%)
USD |
NASDAQ |
May 03, 16:00
45.23
-0.03
(-0.07%)
Pre-Market: 20:00
MoonLake Immunotherapeutics Cash from Financing (TTM): 479.70M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 479.70M |
| September 30, 2023 | 451.29M |
| June 30, 2023 | 451.29M |
| Date | Value |
|---|---|
| March 31, 2023 | 104.69M |
| December 31, 2022 | 119.69M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
104.69M
Minimum
Mar 2023
479.70M
Maximum
Dec 2023
321.33M
Average
451.29M
Median
Jun 2023
Cash from Financing (TTM) Benchmarks
| Qiagen NV | -716.09M |
| LENZ Therapeutics Inc | -- |
| AC Immune SA | 48.17M |
| CRISPR Therapeutics AG | 62.66M |
| Addex Therapeutics Ltd | 5.863M |